Diagnosis of complex disease and response to treatment is often associated with multiple indicators, both clinical and laboratorial. With the use of biomarkers, various mechanisms have been unraveled which can lead to better and faster diagnosis, predicting and monitoring of response to treatment and new drug development. With the introduction of multiplex technology for immunoassays and the growing awareness of the role of immunemonitoring during new therapeutic interventions it is now possible to test large numbers of soluble mediators in small sample volumes. However, standardization of sample collection and laboratory assessments remains suboptimal.
Introduction
Inflammation comprises of a series of coordinated responses to tissue impairment either caused by pathogens or from physical agents such as trauma or radiation. Chronic inflammation in tissue is sustained by activation of both the innate (neutrophils and macrophages) and the adaptive immune system (T and B cells), most commonly via cytokines. As a result of chronic inflammation destruction of tissue may contribute to development and progression of autoimmune disease [1] . Diagnosis of these complex diseases and response to treatment is often associated with multiple indicators, both clinical and laboratorial. With the use of biomarkers, which are measurable indicators used to distinguish precisely, reproducibly and objectively either a normal biological state from a pathological state, or the response to a specific therapeutic intervention [2] , important insights into various immune mechanism have been unraveled. This knowledge can lead to new drug development, better diagnosis, and predict and monitor response to treatment. This approach has led to precision medicine in the form of immunotherapies which have seen exceptional advances throughout the past decade for both autoimmune diseases and cancer [3] . These treatments are designed to elicit or amplify an immune response for cancer treatment or reduce and suppress immune reactivity for autoimmune disorders. In addition to this, there is growing awareness of the role of immune-monitoring during these kinds of interventions. The aftermath of the TGN1412 phase I clinical trial in 2006 revealed that the life threatening events were related to up regulation of immune modulatory proteins such as cytokines and chemokines [4, 5] . Subsequently, there is a growing need for rapid, accurate, sensitive and reproducible technology. With the introduction of multiplex technology for immunoassays it has been possible to test large numbers of soluble mediators in small sample volumes, with the evident benefits such as reduction of sample volume, but also turnaround time and cost [6] [7] [8] .
Although standardization has been prominent in day to day clinical practice, standardization of sample collection and laboratory assessments remains suboptimal. Inconsistency in sample collection can affect the results of biological assays and thus several characteristics require thorough evaluation and standardization [9] . This standardization is not limited to assay validity and reproducibility but also pre-analytical treatment and appropriate specimen types. The aim of the study was to evaluate precision, accuracy and reproducibility of an in-house developed panel of 162 immune related markers, including cytokines, chemokines, growth factors, soluble receptors, and metabolic markers. This marker set was chosen based on their potential role in immune related diseases. In addition we explored the expression of these proteins across three different sample types (serum, EDTA plasma and heparin plasma) as well as the effect of freeze-thawing cycles and expression profile in males and females
Material and methods

Serum and plasma collection
Blood samples were collected from 43 healthy anonymous adult volunteers (11 males and 32 females, mean age 42.6 years, range 25-61 years) using the following blood collection tubes: normal clotting tube (SST II Advance, BD Biosciences) for serum, sodium heparin and EDTA tubes for plasma (all BD Biosciences). All samples were collected in the morning, and were kept at room temperature until further processing. Within 4 h after venepuncture all samples were centrifuged and cell free plasma and serum was stored at -80°C until further analysis. All samples obtained were approved for collection by the medical ethics committee of the University Medical Center Utrecht (protocol 07-125/C). Informed consent was obtained from each individual who donated blood samples.
Protein production in whole blood culture
From 8 donors protein production was induced using heparinized whole blood sample which was stimulated with a combination of 100 ng/ml lippopolysacharide (LPS, Sigma Aldrich, Zwijndrecht, the Netherlands) and 7 µg/ml phytohemagglutinin (PHA, Murex Biotech, Dartford, United Kindom). To prevent any dilution effects 10 µl of stimulus was added to 1 ml whole blood and cultured for 24 and 48 h at 37°C in 5% CO 2 . After culture and centrifugation cell free plasma samples were pooled and frozen at −80°C until further analysis.
Pre-analytical preparation
Before analysis all thawed samples were centrifuged through 0.22 µm spin-X filtration columns (Corning, Corning NY USA) to remove debris. Non-specific (heterophillic) antibodies, which may interfere with the assay, were blocked using Heteroblock (Omega Biologicals, Bozeman, MT, USA) as previously described [10, 11] . If applicable, samples were diluted in high performance elisa buffer (HPE buffer, Sanquin, Amsterdam The Netherlands).
Multiplex immunoassay
All 162 coating, biotin labeled detecting antibodies and recombinant proteins were purchased from various commercial sources (supplemental table 1). Magnetic carboxylated polysterene microspheres were purchased from Luminex (Austin, TX, USA). Covalently coupling of the capture antibodies was performed as previously described (50 µg/ml antibody per 6.25 × 10 6 microspheres [12] . Calibration curves from recombinant proteins were constructed using twofold dilution steps in serum diluent (Bio-Techne, Abington, United Kingdom). Positive control (biotin coated) and negative control (mouse IL-6, BD Biosciences) microspheres were taken along in each sample as previously described [13] . In house assay procedures were as previously described [12, 14, 15] . In short, after pre-analytic treatment 50 µl sample was incubated with 10 µl microsphere suspension (500 per mediator) for 1 h. After automated washing (sheath fluid, 0.5% Tween-20, 0.01%NaN 3 ), 25 µl secondary antibody cocktail (8 µg/ml each) was added and incubated for 1 additional hour and thereafter washed. Next 25 µl of streptavidin R-phycoerythrin (BD biosciences, 25 ng/well) was added and incubated for 20 min. After washing, samples were measured in 100 µl HPE buffer. All incubation steps were performed at room temperature protected from light and with continuous shaking. Acquisition of data was performed using a FlexMAP3D system (Bio-Rad) using xPonent 4.1 software (Luminex). Data analysis was performed using Bioplex manager 6.1.1 (Bio-Rad). All assays were performed at the ISO9001:2008 certified multiplex core facility of the laboratory of translational immunology of the university medical center Utrecht.
Dynamic range standard curve
The assay dynamic ranges were defined by the concentration ranges of the calibration curves covered. To optimize dynamic ranges, we titrated all protein calibrator series (13 points) to a maximum fluorescence intensity of at least 30.000 (FlexMap3D System, Luminex Austin TX USA).
Cross-reactivity
To determine assay cross-reactivity we tested the response of microspheres to single recombinant proteins. Single recombinant proteins were dissolved in HPE buffer and tested at concentrations of 4 times the highest calibration point. Percentage of cross-reactivity was calculated as the ratio of fluorescence intensity in response to a single recombinant protein compared with the maximum fluorescence intensity.
Assay reproducibility
To assess assay reproducibility, we measured sodium heparin 2). Each sample was measured in triplicate and at three different time points to assess the intra-assay and inter-assay variation (n = 9). Intra-assay variation is calculated as the mean CV of the triplicates. For reproducibility of the assay the inter-assay variation is determined as the mean CV for 3 consecutive runs. The acceptance criteria for intra-and inter-assay variation are respectively < 10% and < 15% [16] .
Freeze-Thaw cycles
The effect of freeze-thawing cycles on the stability of proteins is tested by repeatedly freezing and thawing of four stimulated healthy control plasma's (see Section 2.2). These samples underwent three freeze-thawing cycles. Within each cycle samples were snap-frozen in liquid nitrogen, and subsequently placed on dry ice. Next samples were thawed in hand warm water. The first thawing cycle is set as baseline and a deviation of > 10% from baseline in the following cycles was marked as affected.
Detection limits
The lower limit of detection (LLOD) was calculated using estimates of the detection limit based on instrument and sample preparation variables. We assessed the limit of detection (LLOD) and quantification (LLOQ) for all mediators by calculating the average blank MFI (n = 30 over 3 consecutive runs), MFI standard deviation (SD), and 2 * SD. LLOD's were determined by interpolation of the mean blank MFI plus 2 * SD in the 5-parameter logistic standard curves. The LLOQ was calculated as 3 * LLOD. The upper limit of quantitation (ULOQ) was calculated from mean-3 SD of 10 replicates of highest standard point [17] .
Linearity of the assay
To assess assay linearity, four samples were spiked with recombinant in protein calibrator and serial dilutions were made with HPE buffer In addition four stimulated plasma samples were also diluted in HPE buffer. Neat sample measurements (baseline) were set at 100%. For high (natural occurring) concentrations of various proteins, pre-dilutions of 1:10, 1:100 and 1:1000 were made to produce samples within the dynamic range of the assay, set on sodium heparin plasma.
Statistical analysis
All results are expressed as mean of the observed concentration ± SD For calculation of freeze-thaw cycles baseline values were set at 100% and follow-up points were related to this baseline value. Difference between the three different blood collection tubes are analyzed using a one-way ANOVA. A probability (p) value less than 0.05 was considered significantly different. Statistical analysis were performed using the statistical package for social sciences (SPSS) software version 21.0.0 (IBM). For comparison of the different matrices unsupervised heat maps were generated by normalizing all data between minimum (bleu) and maximum (red) for each individual marker using Omniviz 6.1.2.0 (Instem Scientific) and a unsupervised principal component analysis (PCA) was performed using R (version 3.3.2, The R Foundation for Statistical Computing, Vienna, Austria). Graphical visualization of the first and second principal component was plotted using the ggplot2 package.
Results
Assay development and validation
To develop this assay all recombinant protein-antibody combinations were optimized in single bead assays before stepwise expanding the assay with 5 mediators each time into in a multiplex panel. When more than 65 targets were mixed together in any given order we observed that the peak fluorescence intensity of the highest standard curve points were reduced and that the sensitivity was lost at the lower part. Therefore all further assays were performed with a maximum of a 60-plex assay, unless otherwise indicated.
In order to investigate potential cross-reactivity, a full mixture of microspheres and detection antibodies was incubated in the presence of a single protein at a concentration of at least 4 times the highest point used for creating standard curves. At this concentration no cross-reaction was observed with exception of 3 mediators, CCL2 was detected by CCL11 (4.4 ± 1.3%) and CCL13 (10.6 ± 3.1%), MMP1 was detected by MMP8 (5.8 ± 1.7%), and CCL3 was detected by CCL4 (49.1 ± 7.8%). Confirmatory assays were performed using single potential cross-reacting mediators at a concentrations used to create standard curves. Using this lower concentration, cross-reaction of CCL11, CCL13 and MMP8 was not detectable. Cross-reaction between CCL3 and CCL4 was still present, though significantly reduced to 9.3 ± 4.1%.
The LLOD and LLOQ were calculated for each individual mediator and showed that the majority of mediators could be measured in their low physiological range (Table 1) . Intra-and inter-assay variance, expressed as coefficient of variation (CV), was calculated using 8 plasma samples (either stimulated or unstimulated). Intra-assay variance, measured in triplicate over 3 different time points were all < 10% with an average of 5.0% (Table 1) . Unexpectedly OPG could not be assessed as all microspheres coagulated together in stimulated sodium heparin plasma, though this phenomena was not observed in normal biological Assay working range for each mediator was assessed by calculating the lower limit of detection (LLOD) and quantification (LLOD) as well as the upper limit of quantitation (ULOQ) by running 30 samples over 3 consecutive runs, all expressed as pg/ml, except # IFN-b U/ml. Intra-and inter-assay variation expressed as coefficient of variation (VC=SD/mean). Recovery expressed as percentage was calculated by spiking known amounts of each mediator in heat treated plasma samples.
R.C. Scholman et al. Cytokine 106 (2018) 114-124
samples. Inter-assay variance was assed using the same control samples run over 3 different time points. Variance ranged between 1.6 and 34.6% with an average of 12.1% (Table 1) . Thirty-seven mediators expressed a CV > 15% of which 7 expressed a CV > 20% (resistin 20.8%, MMP8 34.6%, S100A8 21.6%, IL-1R4/ST-2 26.9%, VEGF R1 20.2%, erythropoetin-R 23.5%, and galectin-7 24.3%). Recovery was only assessed by spiking known amount of recombinant proteins in heat treated serum samples (n = 10). After a subtraction of their corresponding unspiked sample, recovery was calculated. Recoveries were similar for all mediators (mean 99.8 ± 2.6% Table 1 ) with a range between 89.9% and 107.8%.
Before assessing linearity of dilution, a trial run was performed with 5 sodium heparin plasma samples to set out dilutions for proteins which natural concentrations are above ULOQ or proteins which display a prozone effect, resulting in false negative values or inaccurately low results. Several proteins required pre-dilution (1:10, 1:100 or 1:1000) before assessing linearity of dilution in spike in plasma (supplemental table 2). Overall recovery after linear dilutions in the various matrices used is 101 ± 4% with the largest variation in complex matrices with increased dilutions (1:1 range 91-106%, 1:2 range 86-110%, 1:4 range 87-111% 1:8 range 85-119%, supplemental table 2).
Protein stability upon freeze-thawing
Next we questioned how stability of the various proteins was influenced by freeze-thawing cycles. (Next we questioned the influence of freeze-thawing cycles on the stability of the various proteins) Therefore four stimulated sodium heparin plasma samples underwent three freeze-thaw cycles. No deviation, defined as < 10% difference of baseline, in protein expression was observed in 157 mediators up to 3 cycle (overall recovery 1st cycle 102.3%, 2nd cycle 102.0%, 3rd cycle 102.8%). Four proteins were affected after 1 cycle (recovery IL-29 121 ± 50%, Galectin-7 54 ± 20%, OPG 112 ± 8%, p-selectin 119 ± 7%), and CCL5 was affected after 2 freeze-thawing cycles (recovery 114 ± 12%).
Effect of anticoagulant on immune protein profiling
To assess the impact of anticoagulant, serum, EDTA plasma and sodium heparin plasma was collected from 43 healthy donors and analyzed for all 162 markers, using the various dilutions as described above (for details see supplemental table 2). Considerable variation consisted between serum, EDTA and heparin plasma in detectable protein levels (Fig. 1) . Sixty-six markers were not detectable in various individuals in the different matrices of which in some cases, various mediators, were not detected in more than 75% of the population (EDTA plasma n = 1, serum n = 6 and sodium heparin plasma n = 22, Fig. 1 ). Overall heparin plasma yielded 81.6% of data above LLOD, serum 88.6% and EDTA plasma 96.5%.
Only 19 markers showed similar expression profiles without any significant differences between the three different matrixes (IL-33, CCL11, CCL19, CCL23, CXCL12, adiponectin, adipsin, apelin, leptin, chemerin, leptin, PAI-1, FABP4, TPO, SAA-1, cathepsin-L, PD-1, TNF-R1, TACI and hs-CRP supplemental table 3). All other mediators displayed significant different levels between the various matrices used, of which EDTA plasma and heparin plasma 29 mediators (18%) alike EDTA plasma and serum 58 mediators (36%) alike, and serum and heparin plasma display similarity for 59 markers (37%) in expression profile ( Fig. 2A, supplemental table 3) . To visualize the differences in protein signature between the anticoagulants, data was plotted in a heat map ( Fig. 2A) . Due to the use of similar dilutions factors, CXCL4 and Elastase could only be partially assessed. CXLC4 was above ULOQ in serum as well as the majority of EDTA plasmas, whereas Elastase was above ULOQ in sodium heparin plasma ( Fig. 2A) .
To underscore the differences between the anticoagulants, we performed a principal component analysis which is visualized in Fig. 2B . This analysis shows that the different coagulants cluster separately and that sodium heparin shows the most consistent profile compared to serum and EDTA plasma, of which the latter one shows the most variability among the individuals (Fig. 2B) .
Difference between sexes
Although this population of healthy control donors consists of predominately females (f/m ratio 3:1) there are significant differences in expression profiles between sexes in the various blood drawing tubes. As expected a significant higher expression of adiponectin and leptin was present in females regardless of anti-coagulant (p < .001 for all). Furthermore males expressed a significant higher level of MMP3 in serum and sodium heparin plasma (both p < .001) and CCL28 in serum and EDTA plasma (both p < .01). Individual differences were found in serum for CD40L p < .01. TWEAK (p < .01) and IL-7Ra (p < .05) in EDTA plasma and NGF (p < .01), HGF (p < .01), sIL-2Ra (p < .05) and endoglin (p < .05) in sodium heparin plasma. Expression in healthy controls (%) Fig. 1 . Differences between presence of mediators in serum, EDTA plasma and heparin plasma. Protein profiles were measured in serum (red) EDTA plasma (purple) and Sodium heparin plasma (green) of 43 healthy controls. Shown are 66 mediators that did not have a full spectrum of detectable protein profile in the various anticoagulants. The presence of each individual mediator above the LLOD isshown as percentage of expression. In sodium heparin plasma 22 mediators are undetectable in 75% of healthy controls, whereas respectively n = 1 and n = 6 mediators for EDTA plasma and serum could not be detected. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
R.C. Scholman et al. Cytokine 106 (2018) 114-124
Fig . 2 . Protein expression patterns in serum, sodium heparin plasma and EDTA plasma. 2A) Expression patterns were plotted as heat map showing all various markers in serum (red), sodium heparin plasma (green) and EDTA plasma (purple) of healthy individuals (n = 43). Data was normalized per individual marker (bleu; lowest expression, red; highest expression, black; > ULOQ using similar dilutions). 2B Next PCA was applied on the data set, showing that the various anticoagulant cluster together and the sodium heparin plasma (NaHep/green) displays the lowest variability between the healthy control population compared to serum (SST/red)) and EDTA plasma (EDTA/purple). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
Discussion
With the use of ELISA, the classical gold standard immunoassay, target discovery of immune modulatory switch points have been developed in a variety of autoimmune diseases and cancer. This has led to the introduction of anti-cytokine therapy by administration of anti-IFN antibodies in rheumatoid arthritis in 1974 [18] . Since then, many effective immunotherapeutic treatments using fluorescent bead based assays have been developed replacing the classical ELISA [19, 20] . With the use of this multiplex technology, discovery and monitoring of soluble biomarkers for complex disease phenotypes can be easily achieved, which can be beneficial for diagnosis, immune-monitoring for treatment, disease progression, discovery of potential new drug targets and personalized medicine. Although to date surrogate protein markers for complex diseases are constrained, a multi biomarker disease activity test for rheumatoid arthritis has been developed and implemented in day to day use [10, 21] . The growing interest in multiplex technology also reveals the need for standardization and validation for both technology and sample handling [8, 9] . Since 1990 regulatory agencies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) require stringent validation assays for bioanalytical methods relevant to either drug registration or modifications, which involve accuracy, precision and reproducibility [16] . In this validation study, we show that with use of an open structure bead based technology the majority of immune related markers can be measured reliably in complex matrices such as serum and plasma with low assays variation, good reproducibility from well-to-well, and day to day (Table 1) . Less than 5%, cross reactivity was observed between two structurally related chemokines, namely CCL3 and CCL4. However, it should be noted that the cross-reaction observed of these recombinant proteins are at concentrations that exceeds physiological concentrations observed in plasma and serum, and thus, thereby reducing the chance of cross-reactivity in physiological samples.
To reduce variation due to the matrix effects, it is important to process the samples as quickly as possible by separating the plasma or the serum from cellular components and block interference during the assay of heterophilic antibodies [8, 11, 15, 22] . Especially the later one gives rise to difficulties in immunoassays, resulting in false positive values [23] . As part of FDA criteria for assay validation this issue needs to be addressed, and therefore all samples were blocked using a commercially available blocking agent. We are aware that in many day-today clinical settings, and especially in multi-institutional trials, the handling procedures reflects the unavoidable limitations inherent in transferring patient samples from a clinic to a central laboratory capable of standardized processing. Although temperature and delay of sample handling will affect biomarker concentration [8, 24] , due standardization this effect can be minimized [9] . In our setting, samples were processed in a very well controlled environment, resulting in storage of all samples at −80°C within 4 h after collection, though when longer processing times are expected samples can be placed on ice to keep the biomarker profile stable [8, 15, 25] .
In this study we observed remarkably stable expression of the majority of proteins after 2 freeze-thaw cycles. Again, as these experiments were performed in a controlled environment, it could well be that, with prolonged time (several years) between various freeze-thawing cycles, protein levels will be affected.
In line with others, we demonstrate that the concentration of soluble mediators measured is depended on type of anticoagulant used [7, 22, [26] [27] [28] . We measured proteins signatures in various sequentially taken blood samples from healthy individuals, which were prepared by either spontaneous clotting for serum and two different methods of anticoagulation to create plasma, commonly used in day to day clinical practice. The coagulation cascade is a complex biochemical process which involves activation of platelets and other cellular components, resulting in release of various proteins. On the contrary, several proteins (such as fibrinogen) are used or secluded during the coagulation process. This results in differential expression patterns that are comparable to various plasma types (Fig. 2) , which mainly involves typical platelets related markers such as IL-6, CCL5, CXCL4, CXCL8 and VEGF-A [15, [26] [27] [28] . To rule out the effect of platelets, plasma might be better to mirror the protein profile in vivo. EDTA plasma is generated by chelating calcium, whereas heparin exerts its effect by binding to antithrombin III [29] . By chelating calcium, EDTA results in hypocalcemia which induces a cellular stress reaction resulting in increased levels of IL-1RA, TNFa, G-CSF and M-CSF (Table 2) [30, 31] . Indeed various studies, including this one, these observations are noted, most strikingly for G-CSF in our dataset which a 200 fold higher in EDTA plasma (Table 2 ) compared to serum and heparin plasma [28] .
In this study heparin plasma yields the most undetectable cases in our healthy cohort compared to serum and EDTA plasma (Fig. 1) , however, principal component analysis shows that sodium heparin samples show the least variability in this cohort. This is in line with the study of Wong et al. and Hosnijeh et al. [26, 32] but in contrast with other studies in which heparin yields the highest values [6, 28] . The difference between these studies is the use of either lithium or sodium heparin. Indeed it has been shown that lithium induces a strong inflammatory response via NFκB activation, which results in the release of various immune related proteins (such as IL-6, and TNFa) from a variety of circulating cells [33, 34] . Remarkably OPG could not be detected in sodium heparin stimulated blood. One explanation could be that sodium heparin can form micro precipitates which impacts the sample performance [35] .
Overall in this cohort more than 80% of all proteins detected are significantly different in the various plasma and serum samples. The Observed concentrations (mean value and range) in serum sodium heparin plasma and EDTA plasma of 43 healthy controls. < = < LLOD, > = > ULOQ. #; CXCL4 was run in similar dilutions set on found concentrations in sodium heparin plasma (see supplemental table 2) which resulted in > ULOQ for all EDTA plasma and Serum samples.
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Cytokine 106 (2018) [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] proteins which express similar values across the various biological sample types are mainly the acute phase reactants such as CRP and SAA-1, and the various adipokines, such as leptin and adiponectin. Interestingly, regardless of the anti-coagulant used, the latter ones are, as expected, different between males and females. However, some other unrelated markers are differentially expressed between males and females, which is important to note especially in cohorts were one of the sexes is dominant, such as various autoimmune diseases. Although these differences are depending on which anticoagulant is used it underscoring the effect of anticoagulant used. In conclusion, xMAP technology offers the opportunity to develop and validate in-house assays for a wide variety of mediators to be tested in a single sample. Acceptable well to well and day to day reproducibility are obtained in complex matrices such as serum and plasma. However among other exogenous factors such as assay handling protocols, the expression of mediators is under influence of anti-coagulant used. Our data indicates that sodium heparin plasma might be the favorable matrix to be used for this technology as it shows the most consistent protein profile, with the least differences between males and females compared to serum and EDTA plasma. In addition our data indicates that up to two freeze thawing cycles will have minimal effect on the biomarker profiles.
